Business

MASS. MOVERS

Amag results expected to come up short

ISTOCKPHOTO.COM

Advertisement

Amag Pharmaceuticals Inc. slumped on preliminary fourth-quarter revenue of between $14.3 million and $15 million, lower than the $16 million analysts had estimated. The Lexington company put itself up for sale late last year after lackluster revenue for its anemia drug and a failed merger bid. It received approval for Feraheme from Canadian regulators in December. Amag said it expects fourth-quarter operating costs and expenses of $38 million to $43 million, including restructuring costs and a $2 million termination fee to Allos Therapeutics.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com